Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28600418 | 0.84 | CYP3A4 (0.56) | CYP3A4TSHRPIK3CAALDH1A1HPGD | |
| SCHEMBL27718656 | 0.83 | CD44 (0.54) | CYP3A4TSHRPIK3CAALDH1A1HPGD | |
| SCHEMBL5950773 | 0.81 | ALDH1A1 (0.56) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL6543972 | 0.80 | CD44 (0.50) | CYP3A4TSHRPIK3CAALDH1A1HPGD | |
| SCHEMBL4083590 | 0.79 | CD44 (0.54) | CYP3A4TSHRPIK3CAALDH1A1HPGD | |
| SCHEMBL31484742 | 0.79 | CD44 (0.54) | CYP3A4TSHRPIK3CAALDH1A1HPGD | |
| SCHEMBL4647758 | 0.78 | CYP1A2 (0.59) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| Hydrochloric Acid SCHEMBL28970550 | 0.77 | CYP3A4 (0.54) | CYP3A4TSHRPIK3CAALDH1A1HPGD | |
| SCHEMBL17065502 | 0.76 | ALDH1A1 (0.50) | CYP3A4TSHRALDH1A1HPGDHSD17B10 | |
| SCHEMBL29353343 | 0.75 | ALDH1A1 (0.53) | CYP3A4TSHRALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677727-B | Synthesis method of ceftazidime sulfate | 齐鲁安替制药有限公司 | 2023-11-24 | — | — | CN | claimed |
| CN-116348460-A | Preparation method of BTK degradation agent | 四川海思科制药有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-116323594-A | Preparation method of BTK degradation agent | 四川海思科制药有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-110041202-B | Preparation method of 1, 8-disubstituted naphthalene mononitration derivative | 长江大学 | 2022-04-19 | — | — | CN | claimed |
| CN-110041203-A | A kind of 1,8- bis- replaces the preparation method of naphthalene system condensed-nuclei aromatics mono-nitration derivative | 长江大学 | 2019-07-23 | — | — | CN | claimed |
| CN-102775384-B | Broussone-tine I and J analogue and preparation method and applications thereof | CHINESE ACAD INST CHEMISTRY | 2015-05-27 | — | — | CN | claimed |
| CN-119241622-B | 3′-ONH2Synthesis method of ribonucleotide | 凯莱英生命科学技术(天津)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-12227798-B2 | Methods and compositions for incorporating nucleotides | IsoPlexis Corporation (US) | 2025-02-18 | — | — | US | disclosed |
| US-20250052717-A1 | METHODS AND DEVICES FOR SEQUENCING NUCLEIC ACIDS IN SMALLER BATCHES | QIAGEN SCIENCES, LLC | 2025-02-13 | — | — | US | disclosed |
| CN-119241622-A | 3′-ONH2Synthesis method of ribonucleotide | 凯莱英生命科学技术(天津)有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2025002357-A1 | TETRODOTOXIN DERIVATIVE COMPOUND AND USE THEREOF AS SODIUM CHANNEL BLOCKER | 博璞诺（上海）医药科技发展有限公司 | 2025-01-02 | — | — | WO | disclosed |
| CN-117886871-A | Preparation method of N-deuterated methyl pseudouridine triphosphate | 芜湖华仁科技有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11940413-B2 | Methods and devices for sequencing nucleic acids in smaller batches | IsoPlexis Corporation (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2009117119-A1 | METHODS AND COMPOSITIONS FOR BASE CALLING NUCLEIC ACIDS | INTELLIGENT BIO-SYSTEMS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-1192149-B1 | 1,4-DITHIIN AND 1,4-DITHIEPIN- 1,1,4,4, TETROXIDE DERIVATIVES USEFUL AS ANTAGONISTS OF THE HUMAN GALANIN RECEPTOR | ORTHO MCNEIL PHARM INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-6407136-B1 | EATING, SLEEP, PSYCHOLOGICAL, AND CENTRAL NERVOUS SYSTEM DISORDERS; DIABETES, ALZHEIMER*S DISEASE; HYPOTENSIVE AGENTS, ANALGESICS, ANTIDEPRESSANTS, COGNITION ACTIVATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-06-18 | — | — | US | disclosed |
| US-5446189-A | Diester intermediates for diacid enzyme inhibitor | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5324747-A | Treatment of inflammatory diseases | HOFFMANN-LA ROCHE INC. (US) | 1994-06-28 | — | — | US | disclosed |
| EP-0579066-A2 | N-substituted anilines | F. HOFFMANN-LA ROCHE AG (CH) | 1994-01-19 | — | — | EP | disclosed |
| US-4224237-A | Catalytic process for polyhydric alcohols and derivatives | UNION CARBIDE CORPORATION (US) | 1980-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227798-B2 | Methods and compositions for incorporating nucleotides | NT5C2, NOP2, NT5C3B | CYP3A4 4438/4885TSHR 3450/4885PIK3CA 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.